The antibody cocktail used to treat COVID-19 has been shown to be 100 percent effective against symptomatic cases of the error, according to new data released Tuesday.
Regeneron said his REGEN-COV treatment completely reduced symptomatic infections and lowered the overall infection rate to about 50 percent in about 400 participants who lived with a COVID-19 patient.
Ten out of 186 people who received the treatment contracted COVID-19 but showed no symptoms.
These participants also had lower viral loads and a shorter period of virus shedding, the company said.
The Westchester-based biotechnology giant said the treatment could be used as a “passive vaccine” according to Phase 3 results in the study jointly conducted by the National Institute of Allergy and Infectious Diseases.
In November, the Food and Drug Administration shed light on Regeneron therapy for mild to moderate COVID-19 cases in adults and children.
A “passive vaccine” involves the delivery of antibodies against viruses into the body, unlike traditional vaccines, which activate a person’s immune system to make their own antibodies.
The full results of the study are expected in the second quarter.